Abstract:
The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.
Abstract:
Provided is an anesthetic solution-filled cartridge-type electric dental syringe, wherein the plunger has been shortened but the plunger can nevertheless be extended to the distance necessary to evacuate the anesthetic solution from the cartridge. The syringe comprises: an extension tube into which a plunger is movably inserted, the extension tube being movably disposed in the through hole of a support block and having racks formed in the side surface thereof that are coordinated with the racks of the plunger; and a means for the plunger to draw the extension tube to engage the racks of the extension tube with a pinion when the plunger reaches the middle of the distance corresponding to the anesthetic solution accommodation length of the cartridge. By the engagement of the racks of the extension tube with the pinion, the plunger moves together with the extension tube for the remainder of the distance corresponding to the anesthetic solution accommodation length of the cartridge.
Abstract:
Provided is an anesthetic solution-filled cartridge-type electric dental syringe, wherein the plunger has been shortened but the plunger can nevertheless be extended to the distance necessary to evacuate the anesthetic solution from the cartridge. The syringe comprises: an extension tube (11) into which a plunger (5) is movably inserted, the extension tube being movably disposed in the through hole (14) of a support block (13) and having racks (15, 15) formed in the side surface thereof that are coordinated with the racks (9) of the plunger; and a means for the plunger to draw the extension tube to engage the racks (15, 15) of the extension tube with a pinion (21) when the plunger reaches the middle of the distance corresponding to the anesthetic solution accommodation length of the cartridge. By the engagement of the racks of the extension tube with the pinion, the plunger moves together with the extension tube for the remainder of the distance corresponding to the anesthetic solution accommodation length of the cartridge.
Abstract:
The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in a subject. The thiazole derivative is a compound represented by the formula (I): R1—NH—X—Y—Z wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.
Abstract:
A dopa oxidase inhibitor, a skin-lightening agent and an external preparation for skin; comprising an extract of at least one plant selected from the group consisting of Melia toosendan Sieb. et Zucc., Amomum tsao-ka Crevost et Lemaire. Senecio gracilis and Veratrum nigrum L., or a compound represented by the following Formula (1), as an active ingredient: wherein R represents an acyl group having 1 to 5 carbon atom(s).
Abstract translation:多巴氧化酶抑制剂,皮肤发光剂和皮肤外用剂; 包含至少一种选自Melia toosendan Sieb的植物的提取物。 et Zucc。,Amomum tsao-ka Crevost et Lemaire。 (C),或者下述式(1)表示的化合物作为活性成分,式中,R表示碳原子数为1〜5的酰基。
Abstract:
The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.
Abstract:
Provided are a very safe skin whitening agent, melanin production inhibitor, and dopa oxidase activity inhibitor. Use of kitsunenomago or an organic solvent extract thereof to inhibit the dopa oxidase activity.
Abstract:
Use of haguro-so or an organic solvent extract thereof, or a compound represented by the following formula (I) or a salt thereof, for inhibiting a dopa oxidase activity, for inhibiting melanin production, or for whitening the skin; in the formula (I), R1 and R2, being the same or different, each represent a hydroxyl group, or a C1-4 linear or branched alkoxy group, or R1 and R2 together form a methylenedioxy group; R3 and R4, being the same or different, each represent a hydroxyl group, or a C1-4 linear or branched alkoxy group, or R3 and R4 together form a methylenedioxy group; R5 represents a hydrogen atom, a hydroxyl group, a C1-5 linear or branched alkoxy group, a C1-4 acyl group, or a sugar residue selected from the group consisting of (D-apio-β-D-furanosyl)oxy, (β-D-glucopyranosyl)oxy, (3-O,4-O-dimethyl-D-xylopyranosyl)oxy, (2-O,3-O,4-O-trimethyl-β-D-xylopyranosyl)oxy, and (3-O-methyl-β-D-glucopyranosyl)oxy; R6 and R7 are each a hydrogen atom and R8 and R9 together represent an oxygen atom, or R8 and R9 are each a hydrogen atom and R6 and R7 together represent an oxygen atom.
Abstract:
The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in a subject. The thiazole derivative is a compound represented by the formula (I): R1—NH—X—Y—Z wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.
Abstract:
The invention provides a method for inhibiting dopa oxidase activity, for inhibiting melanin production, or for whitening skin using haguro-so or an organic solvent extract thereof, or a compound of formula (I):